Sun Pharma Shares: A Buy Call Despite Near-Term Headwinds
Despite facing near-term headwinds, Sun Pharma shares have been maintained as a ‘buy’ by Nirmal Bang, driven by the company’s strong growth prospects in India and its specialty pipeline. The brokerage firm expects Sun Pharmaceutical Industries Ltd. to register a CAGR of 8.3% in revenue, 11% in Ebitda, and 8.9% in PAT over FY25-FY27E.
Growth Drivers
The growth is expected to be driven by the company’s continued strong performance in the Indian market, where it has a significant presence. Additionally, the company’s specialty pipeline is expected to contribute to its growth, with new product launches and expansions in existing markets. The pharmaceutical industry in India is expected to grow significantly in the coming years, driven by increasing demand for healthcare services and a growing population.
Ebitda Margins
Nirmal Bang expects Ebitda margins to remain healthy at 30%, driven by margin improvement from existing specialty products and favorable mix changes. However, these will be partially offset by ongoing investments in the expansion of the specialty franchise. The company’s focus on specialty pharmaceuticals is expected to drive growth and profitability in the long term.
Investment Rationale
The investment rationale for Sun Pharma shares is strong, driven by the company’s robust growth prospects, healthy Ebitda margins, and significant presence in the Indian market. The company’s specialty pipeline is expected to drive growth and profitability in the long term, making it an attractive investment opportunity for Indian investors.
Risk Factors
Despite the positive outlook, there are risks associated with investing in Sun Pharma shares. The company faces near-term headwinds, including regulatory challenges and intense competition in the pharmaceutical industry. Additionally, the company’s reliance on its specialty pipeline poses a risk, as any delays or setbacks in product launches could impact growth and profitability.
Conclusion
In conclusion, Sun Pharma shares are a buy call despite near-term headwinds, driven by the company’s strong growth prospects, healthy Ebitda margins, and significant presence in the Indian market. Indian investors looking to invest in the pharmaceutical sector may consider Sun Pharma shares as a long-term investment opportunity.